Prestige Consumer Healthcare Inc. (PBH)

NYSE • Healthcare

$47.8

-$1.66 (-3.4%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$48.96

Previous Close$47.8

Day Range$47.7 - $49.34

Avg. Volume (3M)561.4K

Market Cap$2.2B

P/E Ratio13.3

52 Week Range

$42.62$71.07

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$265.7M100%

Gross Profitminus cost of goods$136.1M51%

Operating Incomeminus R&D and overhead$52.5M20%

Net Incomeminus taxes and the rest$29.1M11%

In plain terms: out of every $100 in revenue, Prestige Consumer Healthcare Inc. keeps $11 as net profit.

Fundamentals & Financials

Revenue (TTM)

$1.1B

Net Income (TTM)

$172M

EPS (TTM)

$3.59

ROA (TTM)

3.77%

Current Ratio

3.23

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-5.9%Q3 2025$0.95

+10.3%Q4 2025$1.07

-1.7%Q1 2026$1.14

-11.5%Q2 2026$1.23

+9.6%Q3 2026$0.98

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +9.6%

Prestige Consumer Healthcare beat estimates on both revenue and adjusted EPS in the first fiscal quarter of 2027, reported on Aug. 6, as revenue rose 6.5% to about $265.7 million and came in above the $250.3 million consensus by 6.1%, with gross margin near 51% and operating margin about 20%. Adjusted EPS of $0.98 topped the $0.89 estimate by 9.6% and was up from $0.95 a year ago, while net income fell 38.5% to about $29.2 million from $47.5 million a year earlier. Operating cash flow came in at about $70.8 million, and the company repurchased about $2.7 million of stock during the period. Next-period consensus calls for EPS of $1.06 on revenue of $293.2 million.

Next report — what to expect

Prestige Consumer Healthcare Inc. (PBH) reports on November 5, 2026. Wall Street is looking for consensus EPS of $1.07 on consensus revenue of $329.1 million; for trailing context, revenue grew +6.5% year over year last quarter. PBH has beaten EPS in 5 of 8 most recent quarters, so focus on results versus these benchmarks.

View full earnings history

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. sells over-the-counter consumer health products in the healthcare sector and trades on the NYSE under PBH. Its portfolio includes branded remedies for pain relief, infant care, sore throat and cough symptoms, eye care, digestive needs, and women's health, and it generated $1.1 billion of revenue in FY2026.

Name

Prestige Consumer Healthcare Inc.

CEO

Ronald Lombardi

Website

www.prestigebrands.com

Industry

Healthcare

Year Founded

1996

Employees

890

Today's Snapshot

AI-generated

PBH closed 3.4% below yesterday's close, in line with a weaker sector. PBH is due to report earnings on 5 November.

Trading Volume

Below 10d avg (554.3K)

529.4K

vs S&P 500 Today

Underperforming Market

-2.84%

Updated: October 23, 2026 at 20:24 UTC

Technical Indicators

1 Buy2 Neutral5 Sell

PBH shows a neutral technical picture driven by mixed short-term momentum and a weak trend. Momentum indicators are largely noncommittal—RSI sits near the midline while MACD registers a small positive reading—yet short-term moving averages lie above the current price and the 200-day average remains well overhead, signaling longer-term resistance. Trend strength is muted with ADX around the high teens, and volatility is moderate with an ATR near 3.2%. Volume measures are soft and classic pivots sit slightly above the price, so upside conviction is limited. Technical takeaway: Neutral.

All signals